PL1713503T3 - Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby - Google Patents

Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby

Info

Publication number
PL1713503T3
PL1713503T3 PL05722948T PL05722948T PL1713503T3 PL 1713503 T3 PL1713503 T3 PL 1713503T3 PL 05722948 T PL05722948 T PL 05722948T PL 05722948 T PL05722948 T PL 05722948T PL 1713503 T3 PL1713503 T3 PL 1713503T3
Authority
PL
Poland
Prior art keywords
inhibition
factor
complement pathway
methods related
alternative complement
Prior art date
Application number
PL05722948T
Other languages
English (en)
Inventor
Vernon Michael Holers
Joshua M Thurman
Christian Taube
Erwin W Gelfand
Gary Steven Gilkeson
Original Assignee
Univ Colorado Regents
Nat Jewish Health
Musc Found For Res Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/015040 external-priority patent/WO2004103288A2/en
Application filed by Univ Colorado Regents, Nat Jewish Health, Musc Found For Res Dev filed Critical Univ Colorado Regents
Publication of PL1713503T3 publication Critical patent/PL1713503T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL05722948T 2004-02-10 2005-02-10 Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby PL1713503T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54359404P 2004-02-10 2004-02-10
PCT/US2004/015040 WO2004103288A2 (en) 2003-05-13 2004-05-13 Method of preventing recurrent miscarriages
US63623904P 2004-12-14 2004-12-14
PCT/US2005/004346 WO2005077417A1 (en) 2004-02-10 2005-02-10 Inhibition of factor b, the alternative complement pathway and methods related thereto
EP05722948.6A EP1713503B1 (en) 2004-02-10 2005-02-10 Inhibition of factor b, the alternative complement pathway and methods related thereto

Publications (1)

Publication Number Publication Date
PL1713503T3 true PL1713503T3 (pl) 2014-02-28

Family

ID=34865159

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05722948T PL1713503T3 (pl) 2004-02-10 2005-02-10 Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby

Country Status (5)

Country Link
EP (2) EP1713503B1 (pl)
AU (1) AU2005212369B2 (pl)
CA (1) CA2561531C (pl)
PL (1) PL1713503T3 (pl)
WO (1) WO2005077417A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1713503E (pt) 2004-02-10 2013-11-14 Nat Jewish Health Inibição do factor b, a via alternativa do complemento e métodos relacionados
JP5707024B2 (ja) 2005-05-26 2015-04-22 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 外傷性脳損傷、脊髄損傷および関連状態を治療するために補体副経路を阻害する作用剤
EP2826788B1 (en) 2006-06-21 2017-12-13 MUSC Foundation for Research Development Targeting complement factor h for treatment of diseases by the use of cr2-fh molecules
CA3154415A1 (en) 2006-10-10 2008-04-17 Regenesance B.V. Anti-sense oligonucleotide for use in facilitating axonal regeneration
JP5872757B2 (ja) 2007-03-14 2016-03-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド ヒト化抗ｂ因子抗体
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
US10239937B2 (en) 2009-11-05 2019-03-26 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
SG185483A1 (en) 2010-05-14 2012-12-28 Univ Colorado Regents Improved complement receptor 2 (cr2) targeting groups
MX2012014975A (es) 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
WO2012093101A1 (en) 2011-01-04 2012-07-12 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
CN104603126B (zh) 2012-06-28 2017-05-31 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
WO2014002054A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
WO2014002051A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
WO2014002058A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
KR20150036481A (ko) 2012-07-12 2015-04-07 노파르티스 아게 보체 경로 조절제 및 그의 용도
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
ES2514165B1 (es) * 2013-03-27 2015-09-09 Consejo Superior De Investigaciones Científicas (Csic) Anticuerpo anti-factor b, composición farmacéutica útil para el tratamiento de enfermedades del complemento y sus aplicaciones
PH12016502062B1 (en) 2014-05-01 2023-01-27 Ionis Pharmaceuticals Inc Compositions and methods for modulating complement factor b expression
KR20240096672A (ko) 2016-04-04 2024-06-26 바이오버라티브 유에스에이 인코포레이티드 항-보체 인자 bb 항체 및 이의 용도
JP7369121B2 (ja) * 2017-10-11 2023-10-25 バイオベラティブ・ユーエスエイ・インコーポレイテッド 補体活性を誘発する方法
IL297444A (en) 2020-04-20 2022-12-01 Genzyme Corp Humanized antibodies against complement factor bb and their use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2043472A1 (en) 1990-06-04 1991-12-05 Mitsutaka Miyabayashi Electrode for secondary battery
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
WO2000021559A2 (en) * 1998-10-09 2000-04-20 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
GB9930659D0 (en) 1999-12-24 2000-02-16 Bio Discovery Ltd Inhibitors of complement activation
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
US20040015040A1 (en) 2002-07-18 2004-01-22 The University Of Cincinnati Flexible, torsionable cardiac framework for heart wall actuation of the natural heart
CA2496834C (en) 2002-09-06 2014-03-18 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
WO2004103288A2 (en) * 2003-05-13 2004-12-02 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of preventing recurrent miscarriages

Also Published As

Publication number Publication date
EP2340850A1 (en) 2011-07-06
AU2005212369B2 (en) 2011-06-23
EP2340850A9 (en) 2012-02-29
AU2005212369A1 (en) 2005-08-25
WO2005077417A1 (en) 2005-08-25
CA2561531A1 (en) 2005-08-25
CA2561531C (en) 2017-05-02
EP1713503B1 (en) 2013-07-31
EP1713503A1 (en) 2006-10-25
EP1713503A4 (en) 2008-08-06

Similar Documents

Publication Publication Date Title
PL1713503T3 (pl) Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby
MX286273B (es) Composiciones y metodos para inhibicion de la via jak.
DK1713503T3 (da) Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
ZA200700351B (en) Compounds, compositions and methods
SG156674A1 (en) Asphaltene inhibition
EP1796489A4 (en) PROTECTIVE SHOES AND METHOD FOR PRODUCING THE SAME
IL182767A0 (en) S-mirtazapine for the treatment of hot flush
IL178888A0 (en) Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives
EP1789055A4 (en) INHIBITORS OF THIAZOLOPYRIDINE KINASE
SI1713503T1 (sl) Inhibicija faktorja B, alternativna komplementa pot in relevantni postopki
GB2418628B (en) Improved laminates and the manufacture thereof
GB0414760D0 (en) The alternative
GB2421540B (en) Padlock
IL177759A0 (en) Cospeptin, cosmedin and their uses
GB0400537D0 (en) Le beanock/the beanock
GB0613700D0 (en) Padlock
GB2420465B (en) The smelly-vision
GB2414745B (en) Euroblock - flood prevention specification
GB0400945D0 (en) The bugcap
GB0406179D0 (en) The portaset
GB0408727D0 (en) The kwik-drobe
GB0409135D0 (en) The gunbi
GB0403902D0 (en) The degravitator
GB0405592D0 (en) The degravitator
GB0424686D0 (en) The speedshaft